SBIO - ETF AI Analysis
Top Page
ALPS Medical Breakthroughs ETF (SBIO)
Rating:47Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, indicating solid momentum in its portfolio.
High-Growth Top Holdings
Most of the largest positions, especially several biotech names, have delivered strong year-to-date performance, helping drive the fund’s returns.
Focused Healthcare Exposure
The fund’s heavy focus on health care and medical breakthroughs gives investors targeted exposure to a sector with significant innovation potential.
Negative Factors
Single-Sector Concentration
With almost all assets in health care, the ETF is highly exposed to swings in one industry rather than being broadly diversified.
U.S.-Only Geographic Exposure
The fund invests only in U.S. companies, which limits global diversification and ties performance closely to the U.S. market.
Moderate Expense Ratio
The ETF’s fees are not especially low, which means a noticeable portion of returns goes toward costs each year.
SBIO vs. SPDR S&P 500 ETF (SPY)
AUM202.41M
RegionNorth America
Expense Ratio0.50%
Beta1.18
IssuerALPS
Inception DateDec 31, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedS-Network Medical Breakthroughs Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume37,220
30 Day Avg. Volume35,575
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
104.44Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering103
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SBIO Summary
SBIO is the ALPS Medical Breakthroughs ETF, which follows the S-Network Medical Breakthroughs Index and focuses on smaller biotech companies working on new drugs and treatments. It mainly holds U.S. health care and biotech stocks that have medicines in late-stage clinical trials, aiming to benefit if these drugs succeed. Well-known names in the fund include ACADIA Pharmaceuticals and Travere Therapeutics. Investors might consider SBIO for growth potential and exposure to cutting-edge medical innovation. However, it is concentrated in biotech, so its price can be very volatile and may move sharply up or down with news about drug approvals or failures.
How much will it cost me?The ALPS Medical Breakthroughs ETF (SBIO) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed and focuses on specialized biotechnology companies, which require more research and expertise to manage effectively.
What would affect this ETF?The ALPS Medical Breakthroughs ETF (SBIO) could benefit from increased demand for innovative health care solutions and advancements in biotechnology, especially as its holdings focus on companies developing groundbreaking treatments in clinical trials. However, the ETF may face challenges from regulatory hurdles, high research and development costs, or broader economic pressures that could impact small to mid-cap biotech firms. Changes in interest rates or shifts in investor sentiment toward riskier assets could also influence its performance.
SBIO Top 10 Holdings
SBIO is essentially a bet on U.S. small- and mid-cap biotech, with names like Crinetics and Apogee acting as steady engines as their trial pipelines move forward. Dianthus and Definium have been rising, giving the fund some welcome momentum, while Oruka’s more mixed, early-stage profile adds volatility rather than clear upside. On the weaker side, CG Oncology and Edgewise have been lagging lately, reminding investors that clinical setbacks can quickly sap energy. Overall, this is a highly concentrated play on experimental drugs rather than diversified health care earnings.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | 4.78% | $9.61M | $8.89B | 186.96% | 61 Neutral | |
| Apogee Therapeutics | 4.50% | $9.03M | $10.11B | 256.82% | 49 Neutral | |
| CG Oncology, Inc. | 3.30% | $6.63M | $6.41B | 156.86% | 58 Neutral | |
| Xenon | 3.30% | $6.62M | $6.28B | 105.07% | 48 Neutral | |
| Dianthus Therapeutics | 3.08% | $6.18M | $5.55B | 400.43% | 61 Neutral | |
| Oruka Therapeutics | 2.88% | $5.77M | $5.46B | 538.65% | 41 Neutral | |
| Travere Therapeutics | 2.80% | $5.61M | $5.20B | 258.91% | 56 Neutral | |
| Definium Therapeutics | 2.49% | $5.00M | $5.57B | 366.89% | 40 Neutral | |
| ACADIA Pharmaceuticals | 2.44% | $4.90M | $4.45B | 11.94% | 75 Outperform | |
| Veradermics, Incorporated | 2.43% | $4.88M | $4.66B | ― | ― |
SBIO Technical Analysis
Neutral
―
Price Trends
58.87
Positive
55.98
Positive
52.41
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SBIO, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 65.11, equal to the 50-day MA of 58.87, and equal to the 200-day MA of 52.41, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SBIO.
SBIO Peer Comparison
Comparison Results
Performance Comparison
SBIO
ALPS Medical Breakthroughs ETF
65.20
32.55
99.69%
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
PBE
Invesco Dynamic Biotechnology & Genome ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents